Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 15/20 | 0.61 |
| ▸ | GPR55 | Q9Y2T6 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2023358 | 1.00 | PIK3CG (0.61) | PIK3CGGPR55CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL12442875 | 1.00 | PIK3CG (0.61) | PIK3CGGPR55CYP11B2CYP1A2CYP3A4 | |
| SCHEMBL2027746 | 0.90 | PIK3CG (0.50) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2022806 | 0.90 | PIK3CG (0.50) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8270164 | 0.90 | PIK3CG (0.50) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4323406 | 0.85 | PIK3CG (0.56) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8237049 | 0.83 | PIK3CG (0.54) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4331424 | 0.82 | PIK3CG (0.52) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4983266 | 0.82 | PIK3CG (0.51) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4327904 | 0.81 | PIK3CG (0.53) | PIK3CGCYP11B2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PIK3CG 1735/4885GPR55 29/4885CYP11B2 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.